Non-Hodgkin Lymphoma | Topics

Combined HDAC, mTOR Inhibition Shows Clinical Efficacy in Relapsed/Refractory Hodgkin Lymphoma
October 15, 2020

This phase 1 study found that vorinostat (Zolinza) in combination with either sirolimus (Rapamune) or everolimus (Afinitor) demonstrated clinical efficacy in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.

Study Identifies Characteristics of CAR T-Cell Products Associated with Outcomes in LBCL
October 07, 2020

Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.

Using HDAC3 Inhibitors to Reverse CREBBP Mutations in Lymphomas
January 13, 2020

This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma.